Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 LVCLF | Healthcare | $0.01 | 0.00 | $12.36M | -5.14 | ― | ― |
Living Cell Technologies ( ($AU:1AI) ) has provided an update. Algorae Pharmaceuticals, identified in the filing as ASX:1AI, disclosed a change in director David Hainsworth’s interests. Hainsworth acquired 30 million
Living Cell Technologies ( ($AU:1AI) ) has provided an update. Algorae Pharmaceuticals reported strong shareholder support at its 2026 annual general meeting, with votes overwhelmingly backing the company’s resolutions. The
Living Cell Technologies ( ($AU:1AI) ) has provided an announcement. Algorae Pharmaceuticals expanded its branded medicines business through partnerships with Sakar, Cadila, Dr. Reddy’s, Zydus, Torrent and Umedica, creating a
Living Cell Technologies ( ($AU:1AI) ) just unveiled an update. Algorae Pharmaceuticals has released a non-deal investor presentation outlining general background information on its activities as of October 2026, while
The latest announcement is out from Living Cell Technologies ( ($AU:1AI) ). Algorae Pharmaceuticals reported that AlgoraeRx has been appointed as one of several suppliers under a non‑exclusive NSW Health
Living Cell Technologies ( ($AU:1AI) ) has issued an update. Algorae Pharmaceuticals has updated its Securities Trading Policy in line with ASX Listing Rule 12.10, signalling a tightening and formalisation
Living Cell Technologies ( ($AU:1AI) ) has provided an update. Algorae Pharmaceuticals, through its wholly owned subsidiary AlgoraeRx, has signed a non‑binding memorandum of understanding and a binding licence and
Living Cell Technologies ( ($AU:1AI) ) just unveiled an announcement. Algorae Pharmaceuticals has scheduled its 2026 Annual General Meeting for 5 November in Melbourne, confirming it will be held as
Living Cell Technologies ( ($AU:1AI) ) has issued an update. Algorae Pharmaceuticals is an AI-driven pharmaceutical company that combines proprietary drug-combination discovery technology with a commercialisation arm supplying generic and
Living Cell Technologies ( ($AU:1AI) ) just unveiled an update. Algorae Pharmaceuticals Limited has notified the ASX of the cessation of 10,000,000 performance rights after the underlying conditions failed to
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| LVCLF | Mar 3, 2027TBA | $12.36M | ― | ― | 0.00 | -5.14 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
